Helyx Industries S.p.A.
MMIL:HLX0.69
EUR
0.00
(0.00%)
ISIN
IT0005451213
Return %
Stock
S&P 500
1Y
- -
14.20
3Y
- -
81.12
5Y
- -
68.34
Capital Structure
EUR
•
in mil. unless spec.Working Capital
EUR
•
in mil. unless spec.Growth Rates
EUR
•
in mil. unless spec.Semi-annual Revenue
EUR
•
in mil. unless spec.Semi-annual Earnings Per Share
EUR
•
in mil. unless spec.Semi-annual Dividends Per Share
EUR
•
in mil. unless spec.Company Description
- CEO
- Nicola Basile
- Full Time Employees
- 19
- Sector
- Health technology
- Industry
- Medical specialties
- Address
- Via Cavour, 20 Udine UD Italy 33100
- IPO Date
- Aug 4, 2021
- Website
- ulissebiomed.com
- Similar Companies
- Business
- Helyx Industries S.p.A. is an Italy-based healthcare biotechnology company focused on the development, manufacture, and commercialization of advanced diagnostic platforms and related molecular testing products for infection, oncology, and broader clinical applications. The company operates through multi-platform ecosystems and offers end-to-end diagnostic solutions, including hardware instruments, consumables, reagents, software, and associated services, with an emphasis on ambient-stable reagents, cloud-enabled data components, and OEM collaboration capabilities. Founded in 2016 (originally Ulisse Biomed SpA) and headquartered in Udine, Italy, Helyx maintains active operations and research activities across Italy and engages strategically with hospital networks and private laboratories for deployment of its Sagitta, NanoHybrid, and Aptavir-based technologies, as well as the Vytro-era PCR offerings for hospital settings and external labs. Main products and services - Sagitta molecular diagnostics platform: integrated diagnostic system for nucleic acid detection across viral, bacterial, and eukaryotic targets; reagents, panels, and accompanying bioinformatics tools - NanoHybrid platform: advanced nucleic acid testing platform with compatible panels and workflow optimization features - Aptavir diagnostic solutions: targeted assays or panels designed for rapid deployment in clinical settings - Reagents and consumables: ambient-stable reagents and end-user consumables compatible with Sagitta and NanoHybrid workflows - OEM and development services: end-to-end product development from bioinformatics to panel design and production; ISO 9001 and ISO 13485 certified for manufacturing and quality management - Software and data components: cloud-based bAPP platform for data management and operational continuity; software integration with diagnostic workflows - Integrated qPCR capabilities: partnerships under a shared platform strategy for real-time PCR solutions, enabling scalable diagnostics across laboratories - Hospital-grade PCR solutions: certified PCR offerings designed for hospital deployment, including hospital networks and regional laboratories Latest major company changes - Rebranding and corporate restructuring: Ulisse Biomed SpA rebrands as Helyx Industries S.p.A., consolidating a multi-division architecture to emphasize three core divisions (Hyris, Vytro, and Sagitta/NanoHybrid/Aptavir) and to broaden OEM and end-to-end development capabilities - Platform expansion and integration: formalization of an integrated platform strategy combining Sagitta, NanoHybrid, and Aptavir with OEM services, enhancing cross-platform interoperability and cloud-enabled data management - Operational and quality enhancements: implementation of dual ISO 9001 and ISO 13485 certifications across OEM services and product development to strengthen compliance and global manufacturing readiness - Strategic partnerships and collaborations: new alliances to accelerate development and deployment of diagnostic platforms in hospital networks and diagnostic labs; emphasis on end-to-end solutions from design to production - Geographic and market expansion: continued expansion of operations and sales reach within Italy and selected European markets, targeting hospitals, clinics, and centralized laboratories with scalable PCR and molecular testing capabilities Industry and business segments - Healthcare biotechnology and diagnostics - In vitro diagnostics (IVD) platforms and assays - Molecular testing reagents and consumables - Diagnostic software and cloud-based data management - OEM and contract development and manufacturing services Target markets and customers - Hospitals and hospital networks - Public and private diagnostic laboratories - Regional and national health systems - Research and development collaborations in translational medicine Geographic operations and corporate structure - Headquarters: Udine, Italy - Primary market focus: Italy with ongoing expansion into broader European markets - Subsidiaries/brands: Sagitta platform line, NanoHybrid, Aptavir, Hyris collaboration for qPCR; Vytro for IVD-certified PCR solutions Founding year and corporate relationships - Founded in 2016 as Ulisse Biomed SpA; rebrands to Helyx Industries S.p.A. in 2026 to reflect a three-division architecture and an expanded product and services portfolio - Operates as an independent Italian corporate entity with potential collaboration and OEM relationships within the broader healthcare diagnostics ecosystem Subsidiaries, partners, and parent relationships - Collaboration framework with Hyris for integrated qPCR platform capabilities - Vytro position as a provider of IVD-certified PCR solutions for hospitals - OEM services arm providing end-to-end development and manufacturing support for external clients Note: Information reflects publicly available disclosures and company communications through 2026, focused on HLX.MI issuer activity and branding changes.